News

Can NVO's Semaglutide Push Create Growth Beyond Cardiometabolic Care?

Novo's semaglutide expansion into liver disease and other obesity-related conditions can unlock growth, but competition and clinical risks loom.

Yahoo·09:02

Altimmune to Participate in Stifel Cardiometabolic Forum

GAITHERSBURG, Md., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in a fireside chat at the Stifel 2026 Virtual Cardiometabolic Forum on Wednesday, September 30, 2026, at 10:30 a.m. ET. A webcast of the fireside chat will be available via the Events section of the Altimmune website. About Altimmune Altimmune is a late clinic

Yahoo·08:00ALT▲+2.2%

Evercore ISI Group Maintains Outperform on Altimmune, Lowers Price Target to $17

Evercore ISI Group analyst Liisa Bayko maintains Altimmune (NASDAQ:ALT) with a Outperform and lowers the price target from $18 to $17.

Benzinga·05:11ALT2.2%

VKTX, GPCR, ALT Stocks Rise: Novo Nordisk Signals Bigger M&A As It Chases Over 5 ‘Multi-Blockbusters’

Novo targets over $23 billion in risk-adjusted pipeline sales by 2035, excluding any contribution from future acquisitions.

Yahoo·01:29ALT▲+2.2%

Why Is Altimmune (ALT) Up 14.2% Since Last Earnings Report?

Altimmune (ALT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo·11:30ALT▲+2.2%

Altimmune’s (ALT) Three Liver Trials Move Forward At Once

On August 12, Altimmune (NASDAQ:ALT) reported second quarter results that read less like a routine earnings update and more like a status check on three separate diseases at the same time. The clinical-stage biopharmaceutical company disclosed a newly launched global Phase 3 trial in MASH, positive Phase 2 data in alcohol use disorder, and completed […]

Yahoo·22:27ALT▲+2.2%

Kodiak's Q2 Loss Wider Than Expected, Pipeline Development in Focus

KOD's Zenkuda advances toward regulatory submission as its pipeline gains momentum. Key clinical data is expected later in 2026.

Yahoo·10:14

ALT's Q2 Loss Narrower Than Expected, Pemvidutide's Studies in Focus

Altimmune posts a narrower Q2 loss. Its $519M in cash supports operations into 2029, while pemvidutide advances across liver and AUD studies.

Yahoo·12:14ALT▲+2.2%

Altimmune: Pemvidutide Performs, But A Long Wait Ahead

SeekingAlpha·09:48ALT▲+2.2%

Altimmune Inc (ALT) (Q2 2026) Earnings Call Highlights: Advancing MASH and AUD Pipelines with ...

Altimmune reports positive Phase 2 AUD data and rapid progress in its MASH Phase 3 trial, backed by $519 million in cash.

Yahoo·19:03ALT▲+2.2%

Altimmune, Inc. (ALT) Q2 2026 Earnings Call Transcript

SeekingAlpha·10:37ALT▲+2.2%

Altimmune Q2 Earnings Call Highlights

BLTE Stock Rises as FDA Grants Priority Review to Tinlarebant NDA

Belite Bio's tinlarebant wins FDA priority review for Stargardt Disease, with a decision expected in February 2027 after positive phase III data.

Yahoo·08:54